ROARABLE // PRO
GLOBAL DESKS // NYC --:--:-- NYSE
US TAPE
ROAR ▸
COMP <GO>

CUVL vs DXST // EV/EBITDA & P/E VALUATION

Clinuvel Pharmaceuticals Limited (NASDAQ) VS. Decent Holding Inc (Class A) (NASDAQ) • 15-METRIC TALLY: CUVL 7 — DXST 1
■ METRIC PARITY
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (CUVL VS. DXST) EMERALD CELL = QUANTITATIVE EDGE
INSTITUTIONAL METRIC CUVL DXST SPREAD (A - B) ADVANTAGE DEDICATED URL
Gross Profit Margin 81.20% 26.20% +55.00 CUVL /gross-margins <GO>
Return on Invested Capital (ROIC) — — — TIE /roic <GO>
EV/EBITDA & P/E Valuation ACTIVE 9.7x — — TIE /valuation <GO>
Free Cash Flow Yield 10.51% — — TIE /fcf-yield <GO>
Operating Margin 43.40% -1.10% +44.50 CUVL /operating-margins <GO>
Net Profit Margin 37.80% -2.50% +40.30 CUVL /net-margins <GO>
Revenue Growth (YoY) 5.50% 12.20% -6.70 DXST /revenue-growth <GO>
Dividend Yield & FCF Payout Safety 0.66% 0.00% +0.66 CUVL /dividend-safety <GO>
Altman Z-Score & Debt/Equity — — — TIE /balance-sheet <GO>
Piotroski F-Score Quality 6/9 2/9 +4.00 CUVL /piotroski-score <GO>
Options Implied Move & Put/Call Skew — — — TIE /options-implied-move <GO>
RSI-14 & 200D SMA Momentum 37.7 27.1 +10.54 CUVL /rsi-technicals <GO>
10Y Yield & FRED Macro Beta — — — TIE /macro-sensitivity <GO>
Forward P/E Multiple 10.3x — — TIE /forward-pe <GO>
Enterprise Scale & Market Cap $257.8M $2.4M $255.4M CUVL /market-cap <GO>
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
FISCAL YEAR CUVL REV DXST REV CUVL GROSS % DXST GROSS % CUVL FCF DXST FCF
FY 2025 $61.1M $12.9M 81.2% 26.2% $27.1M -$3.5M
FY 2024 $57.9M $11.5M 81.5% 27.8% $20.1M -$440.5K
FY 2023 — $9.4M — — — $1.6M
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
CUVL // BETA —
DXST // BETA —